Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Mark Levenson, Weili He, Jie Chen, Yixin Fang, Douglas Faries, Benjamin A. Goldstein, Martin Ho, Kwan Lee, Pallavi Mishra-Kalyani, Frank Rockhold, Hongwei Wang & Richard C. Zink. (2023) Biostatistical Considerations When Using RWD and RWE in Clinical Studies for Regulatory Purposes: A Landscape Assessment. Statistics in Biopharmaceutical Research 15:1, pages 3-13.
Read now
Read now
Sonia M. Thomas, Kwanhye Jung, Hengrui Sun, Matthew A. Psioda, Pedro Miguel Quibrera & Stephen M. Strakowski. (2020) Enhancing clarity of clinical trial safety reports for data monitoring committees. Journal of Biopharmaceutical Statistics 30:6, pages 1147-1161.
Read now
Read now
Wenyu Ye, Haya Ascher-Svanum, Yuka Tanji, Jennifer A Flynn & Michihiro Takahashi. (2011) Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan. Patient Preference and Adherence 5, pages 611-617.
Read now
Read now
Articles from other publishers (10)
Yumi Aoki, Yukari Yaju, Tomohiro Utsumi, Leigh Sanyaolu, Marianne Storm, Yoshikazu Takaesu, Koichiro Watanabe, Norio Watanabe, Edward Duncan & Adrian GK Edwards. (2022) Shared decision-making interventions for people with mental health conditions. Cochrane Database of Systematic Reviews 2022:11.
Crossref
Crossref
Tomoyuki Nakamura, Masaru Tomita, Susumu Hirota, Takamasa Matsunaga & Naohisa Uchimura. (2022) Impact of Selected Initial Titration Schedules on Safety and Long-Term Effectiveness of Lamotrigine for the Treatment of Mood Disorders. Journal of Clinical Psychopharmacology 42:4, pages 350-356.
Crossref
Crossref
Barbara Iruretagoyena, Carmen Paz Castañeda, Cristian Mena, Camila Diaz, Ruben Nachar, Juan Pablo Ramirez-Mahaluf, Alfonso González-Valderrama, Juan Undurraga, James H. Maccabe & Nicolas A. Crossley. (2021) Predictors of clozapine discontinuation at 2 years in treatment-resistant schizophrenia. Schizophrenia Research 235, pages 102-108.
Crossref
Crossref
Harmen R. Moes, Jerney W.M.J. Groenendal-Laurensse, Martje Drent, Gerrit Tissingh & Teus van Laar. (2020) Predictors of Time to Discontinuation of Levodopa-Carbidopa Intestinal Gel Infusion: A Retrospective Cohort Study. Journal of Parkinson's Disease 10:3, pages 935-944.
Crossref
Crossref
Emily L. ButlerEric B. Laber, Sonia M. DavisMichael R. Kosorok. (2018) Incorporating Patient Preferences into Estimation of Optimal Individualized Treatment Rules. Biometrics 74:1, pages 18-26.
Crossref
Crossref
Gary G. KochLaura Elizabeth Wiener. (2016) Commentary for the Missing Data Working Group's perspective for regulatory clinical trials, estimands, and sensitivity analyses. Statistics in Medicine 35:17, pages 2887-2893.
Crossref
Crossref
Michael O'Kelly & Bohdana RatitchSonia Davis. 2014. Clinical Trials with Missing Data. Clinical Trials with Missing Data
130
184
.
Michael O'Kelly & Bohdana Ratitch. 2014. Clinical Trials with Missing Data. Clinical Trials with Missing Data
409
421
.
Michihiro Takahashi, Shinji Fujikoshi, Jumpei Funai, Levent Alev & Masaomi Iyo. (2014) Predictors of Discontinuation of Antipsychotic Therapy in Patients with Acute Schizophrenia: A 1-Year Observational Study with More Than 1000 Patients. Open Journal of Psychiatry 04:04, pages 364-371.
Crossref
Crossref
Robert Rosenheck & Haiqun Lin. (2014) Noninferiority of Perphenazine vs. Three Second-Generation Antipsychotics in Chronic Schizophrenia. Journal of Nervous & Mental Disease 202:1, pages 18-24.
Crossref
Crossref